Bayer Yakuhin Files Anti-cancer Drug Nexavar(R) for the Treatment of Advanced Renal Cell Carcinoma.
Nexavar(R) is a drug to suppress cancer growth by stopping the signalling cascade for proliferation of tumor cells and inhibiting angiogenesis which generates vessels to the newly proliferated tumor cells. In ASCO 2005, a prolongation of progression-free survival period was presented using the data of global Phase III which more than 900 RCC patients joined. According to that, time to progression or death on placebo group was 84 days, whereas it was 167 days (p<0.000001) on the group treated by Nexavar(R). In ASCO 2006 held in this June, an interim data on the overall survival was presented to show positive results of Nexavar(R).
In Japan, clinical trials of Nexavar(R) for the treatment of RCC started in 2002 and preferable data to support the efficacy and safety of Nexavar(R) was obtained to file today.
Once approved, it will be commercialized as Nexavar(R) in Japan as well. The registration of this product name was already accepted as a trademark in Japan.
Refer the URL below to know about Renal Cell Carcinoma in detail.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Jun 30, 2006|
|Previous Article:||Takeda Pharmaceutical to Obtain Exclusive Right to Develop and Market Hematide.|
|Next Article:||Suntory, Ochanomizu University Jointly Confirm That Sesamin Helps Lower Blood Sugar Level.|